IR-Med Inc. (OTCQB:IRME)
Roy Govrin, Ph.D., currently serves as a Physicist and Algorithm Developer at IR Med since December 2021. Prior experience includes roles as Project Manager and Algorithm Developer at Nanoghost from April 2020 to July 2021, Senior Researcher at ARAD GROUP for a brief period in early 2020, and Research Physicist at Technion - Israel Institute of Technology from October 2012 to January 2020, where Roy focused on developing atomic force microscopy methods for solid-liquid interaction studies. Additionally, Roy was a Physicist in the 3D Imaging Group at Intel Corporation from July 2010 to October 2012, contributing to imaging system development and image processing algorithms validation. Early career experience includes serving as a Psychometric Exam instructor at Lachman from January 2007 to April 2010. Educational qualifications include multiple Bachelor of Science degrees in Physics and Biology from Technion - Israel Institute of Technology and the University of Hawaii at Manoa, achieved between 2007 and 2012.
This person is not in any teams
IR-Med Inc. (OTCQB:IRME)
IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company’s AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions. PressureSafe, the company’s first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contributes to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue analysis, and in modeling and analysis of subcutaneous tissue.